Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Ondine Biomedical, Inc. (LSE:OBI): Nasal Photodisinfection Technology Draws Investor Attention

Ondine Biomedical is a Canadian life sciences company developing light-activated antimicrobial therapies, with its Steriwave product used to reduce pathogens in the nose before surgery. The 5.13% share-price gain on 20 October, 2026 came as investors follow adoption trends.

Ankur Sharma | 21 October 2026

IXICO Plc (LSE:IXI): Neuroscience Trial Analytics Back in Focus as Shares Advance

IXICO is a London-based specialist that analyses brain imaging data for pharmaceutical and biotech companies running clinical trials in neurological diseases. Its services help sponsors measure whether experimental treatments are affecting the brain. The 9.68% share-price gain on 20 October, 2026 returned attention to …

Ankur Sharma | 21 October 2026

Bioventix Plc (LSE:BVXP): Diagnostic Antibody Royalties Support Share-Price Gain

Bioventix is a Surrey-based biotechnology company that creates high-affinity sheep monoclonal antibodies for use in blood tests run on large automated diagnostic analysers. Its antibodies are used in tests for vitamin D, hormones and cardiac markers. The 7.91% share-price gain on 20 October, 2026 …

Ankur Sharma | 21 October 2026

ProBiotix Health PLC (LSE:PBX): Nine-Month Sales Growth Drives Shares Higher as Commercial Scale Builds

ProBiotix Health is a life sciences company that develops probiotic formulations designed to support cardiometabolic health, including cholesterol management. It supplies ingredients and finished products to partners in food supplement and nutraceutical markets around the world. The 15.16% share-price gain followed a Q3 trading …

Ankur Sharma | 21 October 2026

AOTI Stock Watch: Can Medical Technology Demand Support the Growth Story? (LSE:AOTI)

AOTI, Inc. The latest available review suggests the following focus: As of 20 October 2026, the available review did not establish a verified company-specific announcement that conclusively explains a fresh move in AOTI, Inc.. The stock can still attract attention because investors are reassessing …

Ankur Sharma | 21 October 2026

AIM-Listed Molecule Group (LSE:MOL) Jumps 1.94% as Rebranded ePharmacy Platform Draws Fresh Interest

The rebrand had been flagged in August, when management said a specialist naming agency was developing a new identity for the enlarged group. Its arrival in October gives the market a fresh reason to revisit the story.

Ankur Sharma | 21 October 2026

AIM-Listed Faron Pharmaceuticals (LSE:FARN) Rises 1.71% as BEXERA Phase 2b Trial Gets Under Way

LSE:FARN has also remained in the spotlight following its R&D Day on 8 October, when management and external experts set out the case for bexmarilimab across blood cancers and solid tumours. Biotech investors often reposition after such events as they digest the data and …

Ankur Sharma | 21 October 2026

AIM-Listed Provexis (LSE:PXS) Rises 1.50% as Record Fruitflow Sales Point to Stronger Second Half

Fruitflow is a natural extract from tomatoes that has been shown in human trials to reduce the propensity for aberrant blood clotting, which is associated with cardiovascular disease, heart attack and stroke. It is available as a spray-dried powder that can be included in …

Ankur Sharma | 21 October 2026

AIM-Listed TheraCryf (LSE:TCF) in Focus as Ox-1 Addiction Drug Races Toward Australian Phase 1 Approval

LSE:TCF has been a popular retail stock, and news flow has accelerated in recent weeks with the appointment of a clinical partner in Australia and confirmation that the programme remains on track for clinic readiness by the end of 2026.

Ankur Sharma | 21 October 2026

4basebio Capital Raise Puts Shareholder Approval and Funding Runway in Focus (LSE:4BB)

4basebio PLC (LSE:4BB) is being considered in the context of the FTSE AIM All-Share, where smaller listed businesses can react sharply to fresh disclosures, liquidity changes and shifts in risk appetite. The latest available review suggests the following focus: The proposed capital raise remains …

Ankur Sharma | 21 October 2026
Support

Hi! How can we help you today?

Loading…